US FDA approves Eisai, Biogen Alzheimer's drug - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.

Biogen shares, which had been halted, were up 5% at $285.19.

Initial patient access will be limited by a number of factors including reimbursement decisions from Medicare, the US government insurance program for Americans aged 65 and older who represent some 90% of individuals likely to be eligible for Leqembi. The US Centers for Medicare & Medicaid Services said on Friday that current coverage restrictions for drugs approved under the accelerated pathway could be reconsidered based on its ongoing review of available information.

Lecanemab is intended for patients with mild cognitive impairment or early Alzheimer’s dementia, a population that doctors believe represents a small segment of the estimated 6 million Americans currently living with the memory-robbing illness.

I'm really grateful for all the efforts you have render to me with my little investment of R5000 and with joy over me after withdrawing R60,000 with your help Lisa_berry77 thank you for everything you have done for me and my family Lisa_berry77

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Data Sciences Corporation achieves top-tier Commvault Market Builder status - IT News Africa - Up to date technology news, IT news, Digital news, Telecom news, Mobile news, Gadgets news, Analysis and ReportsEnterprise IT service provider Data Sciences Corporation has become the first South African partner to achieve the top-tier Commvault Market Builder partner status, marking them as one of the leading Commvault partners locally and across the globe. This achievement gives Data Sciences a competitive edge, allows them to leverage enhanced pricing discounts, and affords them […]
Source: ITNewsAfrica - 🏆 27. / 59 Read more »